Filgrastim
Also known as: filgrastim, G-CSF, Granix, Neupogen, Nivestim, Nivestym, r-metHuG-CSF, Zarxio
Source Filgrastim at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Filgrastim is a recombinant form of human granulocyte‑colony stimulating factor (G‑CSF) approved for prescription use. It is given to patients receiving myelosuppressive chemotherapy to stimulate neutrophil recovery, thereby reducing the risk of febrile neutropenia and allowing dose‑dense or dose‑intense treatment schedules.
Mechanism of Action
Filgrastim binds the G‑CSF receptor on hematopoietic progenitor cells in the bone marrow. This activates intracellular JAK/STAT and MAPK pathways, promoting proliferation, differentiation, and survival of neutrophil precursors. The result is an accelerated rise in circulating neutrophils, improving innate immune defence during periods of chemotherapy‑induced marrow suppression.
What the Research Shows
Clinical trials have shown filgrastim enables intensified chemotherapy without added toxicity. In a randomized Ewing sarcoma study, daily filgrastim between cycles allowed a 2‑week interval schedule, improving 5‑year event‑free survival from 65% to 73% (P=.048). A large breast‑cancer trial demonstrated that filgrastim‑supported dose‑dense regimens reduced severe neutropenia and yielded better disease‑free (RR = 0.74) and overall survival (RR = 0.69). European (EORTC) and American (ASCO) guideline updates, based on systematic reviews of randomized and meta‑analytic data, recommend prophylactic filgrastim when chemotherapy carries a ≥20% febrile neutropenia risk, especially for dose‑dense protocols.
Reported Benefits
Evidence indicates filgrastim lowers the incidence of febrile neutropenia, shortens neutropenia duration, and reduces chemotherapy dose delays or reductions. By maintaining planned dose intensity, it has been linked to improved disease‑free and overall survival in dose‑dense breast cancer and to higher event‑free survival in localized Ewing sarcoma. Guidelines endorse its use to protect high‑risk patients and to support regimens where dose intensity is critical for cure.
Limitations of the Evidence
Most data focus on adult solid tumours and selected pediatric sarcomas; evidence for other malignancies is limited. The benefit on long‑term survival is clear in some trials (e.g., breast cancer) but not uniformly demonstrated across all cancers. Guideline recommendations rely on risk thresholds that may vary between institutions, and real‑world practice shows inconsistent prophylactic use. Biosimilar filgrastim products are considered equivalent, but direct comparative outcomes are not detailed in the cited abstracts.
Safety Considerations
Common adverse effects reported with filgrastim include bone pain, injection‑site discomfort, and transient leukocytosis. Rare but serious events such as splenic rupture, allergic reactions, or acute respiratory distress syndrome have been described in broader pharmacovigilance data, though not in the cited trials. Caution is advised in patients with known hypersensitivity to G‑CSF products and in those with myeloid malignancies where stimulation of malignant clones could be a concern.
How It Is Administered
Filgrastim is administered by subcutaneous or intravenous injection, typically once daily during the neutropenic recovery phase between chemotherapy cycles. Dosing in trials has used weight‑based regimens (e.g., 5 µg/kg per day) for a few consecutive days after each chemotherapy course. Formulations are supplied as sterile solution for injection.
Routes of Administration
Goals & Uses
- Severe chronic neutropeniaHematologyModerate
- Chemotherapy‑induced neutropeniaHematologyHigh
- Reduction of chemotherapy-induced febrile neutropeniaOncology / Supportive CareHigh
- Acceleration of neutrophil recovery post bone marrow transplantTransplantationHigh
- Severe chronic neutropenia managementHematologyHigh
- Peripheral blood stem cell mobilizationHematology / TransplantationHigh
- Acute radiation syndrome (hematopoietic subsyndrome)Radiation EmergencyModerate
Contraindications
- Hypersensitivity to filgrastim or E. coli‑derived proteinsAllergyHigh
- Hypersensitivity to filgrastim or E. coli-derived proteinsAllergy / ImmunologyHigh
- Use in myeloid malignancies (AML/CML) without specific justificationOncologyHigh
- Sickle cell diseaseHematologyModerate
Adverse Effects
- Acute respiratory distress syndrome (ARDS)PulmonaryRare
- Splenomegaly / splenic ruptureOrgan ToxicityUncommon
- Bone painMusculoskeletalCommon
- Injection site reactionsLocalCommon
- LeukocytosisHematologicRare
- ThrombocytopeniaHematologicUncommonLow platelet count
- FeverSystemicCommonElevated body temperature
- SplenomegalyHematologicUncommon
- Injection‑site reactionLocalCommon
- Bone pain / musculoskeletal painMusculoskeletalCommon
Drug Interactions
- Cytotoxic chemotherapy agentsModerate
- Chemotherapeutic agentsHigh
- BleomycinModerate
- CorticosteroidsLow
- LithiumLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Elderly (>65 years)AgeRelative
- Pediatric patientsAgeRelative
- Patients with sickle cell diseaseHematologic DisorderRelative
- Pediatric patients (<2 years)AgeRelative
Regulatory Status
- European UnionApprovedApproved: Chemotherapy‑induced neutropenia, Peripheral blood stem cell mobilizationApproved under EMA centralized procedure
- United StatesApprovedApproved: Chemotherapy‑induced neutropenia, Peripheral blood stem cell mobilization, Severe chronic neutropeniaMarketed as Neupogen, Zarxio
- United KingdomApprovedApproved: Chemotherapy‑induced neutropenia, Peripheral blood stem cell mobilizationAvailable via NHS formularies
Approved by FDA in 1991 (Neupogen). Multiple biosimilars approved in the US and EU. Not interchangeable with pegfilgrastim without clinical reassessment.
Evidence & Sources
- Journal ArticleModerateWomer RB, et al.2012-01-01T00:00:00.000000Z
- Journal ArticleHighAapro MS, et al.2011-01-01T00:00:00.000000Z
- Journal ArticleHighSmith TJ, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleModerateCitron ML, et al.2003-01-01T00:00:00.000000Z
Frequently Asked Questions
When should filgrastim be given during chemotherapy?
Guidelines advise administering filgrastim after each chemotherapy cycle, once the absolute neutrophil count falls below a predefined threshold, to promote rapid neutrophil recovery before the next cycle.
Can filgrastim replace dose reductions in high‑risk patients?
Evidence from dose‑dense breast‑cancer and Ewing‑sarcoma trials shows filgrastim can maintain planned dose intensity, reducing the need for dose reductions or delays in patients at high risk of febrile neutropenia.
What are the most common side effects?
Bone pain and mild injection‑site reactions are the most frequently reported adverse events; they are usually self‑limited and can be managed with analgesics if needed.
Are biosimilar versions as effective as the original product?
European and American guideline updates consider approved biosimilar filgrastim products clinically equivalent, although the cited literature does not present head‑to‑head comparative trials.
Is filgrastim used for conditions other than chemotherapy‑induced neutropenia?
The abstracts focus on prophylaxis for chemotherapy‑related neutropenia; other indications such as radiation‑induced marrow suppression are mentioned in guidelines but not detailed in the provided studies.
What is Filgrastim?
Filgrastim is a recombinant form of human granulocyte‑colony stimulating factor (G‑CSF) approved for prescription use. It is given to patients receiving myelosuppressive chemotherapy to stimulate neutrophil recovery, thereby reducing the risk of febrile neutropenia and allowing dose‑dense or dose‑intense treatment schedules.
What is Filgrastim used for?
Filgrastim is educationally associated with: Severe chronic neutropenia, Chemotherapy‑induced neutropenia, Reduction of chemotherapy-induced febrile neutropenia, Acceleration of neutrophil recovery post bone marrow transplant, Severe chronic neutropenia management, Peripheral blood stem cell mobilization, Acute radiation syndrome (hematopoietic subsyndrome). Educational only — not medical advice.
How is Filgrastim administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Filgrastim?
Reported adverse effects include: Acute respiratory distress syndrome (ARDS), Splenomegaly / splenic rupture, Bone pain, Injection site reactions, Leukocytosis, Thrombocytopenia, Fever, Splenomegaly, Injection‑site reaction, Bone pain / musculoskeletal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Filgrastim?
Recorded contraindications: Hypersensitivity to filgrastim or E. coli‑derived proteins, Hypersensitivity to filgrastim or E. coli-derived proteins, Use in myeloid malignancies (AML/CML) without specific justification, Sickle cell disease. Consult a qualified clinician before use.